ACE2 and lung carcinoma: As shown in Figure 8, lung cancer patients infected with SARS-CoV-2 may have a worse outcome because SARS-CoV-2-induced ACE2 and NPC1 elevation, which in turn promotes further SARS-CoV-2 invasion, may influence the immune subtypes of LUSC and immune infiltration in CD8+T of LUAD, and affect the sensitivity of anti-cancer drug.